HomeCompareZLDAF vs PLD

ZLDAF vs PLD: Dividend Comparison 2026

ZLDAF yields 609.16% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZLDAF wins by $292131.41M in total portfolio value
10 years
ZLDAF
ZLDAF
● Live price
609.16%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$292137.32M
Annual income
$220,826,387,190.95
Full ZLDAF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ZLDAF vs PLD

📍 ZLDAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZLDAFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZLDAF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZLDAF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZLDAF
Annual income on $10K today (after 15% tax)
$51,778.75/yr
After 10yr DRIP, annual income (after tax)
$187,702,429,112.31/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, ZLDAF beats the other by $187,698,390,995.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZLDAF + PLD for your $10,000?

ZLDAF: 50%PLD: 50%
100% PLD50/50100% ZLDAF
Portfolio after 10yr
$146071.61M
Annual income
$110,415,568,958.06/yr
Blended yield
75.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ZLDAF
No analyst data
Altman Z
-200.0
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZLDAF buys
0
PLD buys
0
No recent congressional trades found for ZLDAF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZLDAFPLD
Forward yield609.16%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$292137.32M$5.91M
Annual income after 10y$220,826,387,190.95$4,750,725.19
Total dividends collected$286203.91M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ZLDAF vs PLD ($10,000, DRIP)

YearZLDAF PortfolioZLDAF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$71,616$60,916.18$11,241$540.96+$60.4KZLDAF
2$484,347$407,718.13$13,019$991.13+$471.3KZLDAF
3$3,095,297$2,577,045.67$15,801$1,870.97+$3.08MZLDAF
4$18,703,566$15,391,597.96$20,609$3,701.21+$18.68MZLDAF
5$106,933,266$86,920,450.25$29,919$7,867.97+$106.90MZLDAF
6$578,855,369$464,436,774.20$50,631$18,617.74+$578.80MZLDAF
7$2,969,008,370$2,349,633,124.95$105,528$51,352.20+$2968.90MZLDAF
8$14,439,931,036$11,263,092,080.14$287,364$174,449.42+$14439.64MZLDAF
9$66,645,727,013$51,195,000,804.51$1,081,760$774,280.77+$66644.65MZLDAF
10$292,137,315,095$220,826,387,190.95$5,908,209$4,750,725.19+$292131.41MZLDAF

ZLDAF vs PLD: Complete Analysis 2026

ZLDAFStock

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Full ZLDAF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ZLDAF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZLDAF vs SCHDZLDAF vs JEPIZLDAF vs OZLDAF vs KOZLDAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.